Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer

Lung Cancer

Volumn 68, Issue 1, 2010, Pages 84-88

  Edelman, Martin J ^a   Burrows, Whitney ^a   Krasna, Mark J ^a   Bedor, Michelle ^a   Smith, Ruth ^a   Suntharalingam, Mohan ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Bortezomib; Chemoradiation; Locally advanced; Lung cancer; Multimodality therapy; Pneumonitis

Indexed keywords

BORTEZOMIB; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MORTALITY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; RADIATION DOSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; POSTOPERATIVE COMPLICATIONS; PROTEASE INHIBITORS; PYRAZINES; RADIOTHERAPY; RESPIRATORY INSUFFICIENCY;

EID: 77649180962     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.05.003     Document Type: Article

References (25)

1. Mountain C.F. Revisions in the international staging system for staging lung cancer. Chest 111 (1997) 1710-1717
2. Edelman M.J., Gandara D.R., Roach M., and Benfield J.R. Multimodality therapy in stage III non-small cell lung cancer. Ann Thorac Surg 61 (1996) 1564-1572
3. Rusch V.W., Albain K.S., Crowley J.J., Rice T.W., Lonchyna V., Mekenna R., et al. Surgical resection of stage IIIa and stage IIIb non-small-cell lung cancer after concurrent induction chemoradiotherapy. J Thorac Cardiovasc Surg 105 (1993) 96-106
4. Rusch V.W., Giroux D.J., Kraut M.J., Crowley J., Hazuka M., Winton T., et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25 January (3) (2007) 313-318
5. Albain KS, Swann, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 2005;23:16S, Part I of II (June 1 Suppl.), 2005:7014.
6. Edelman M.J., Suntharalingam M., Burrows W., Kwong K.F., Mitra N., Gamliel Z., et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage iii non-small cell lung cancer. Ann Thorac Surg 86 3 (2008) 903-910
7. Sonett J., Suntharalingam M., Edelman M.J., Patel A.B., Gamliel Z., Doyle A., et al. Pulmonary resection following neoadjuvant high dose cruative intent radiotherapy (>59 GY) and concurrent chemotherapy. Ann Thorac Surg 78 (2004) 1200-1205
8. Patel N.M., Nozaki S., Shortle N.H., Bhat-Nakshatri P., Newton T.R., Rice S., et al. Paclitaxel sensitivity of breast cancer cells with constituitively active NF-kB is enhanced by IkBa super-repressor and parthenolide. Oncogene (2000) 4159-4169
9. Russo S.M., Tepper J.E., Baldwin Jr. A.S., Liu R., Adams J., Elliott P., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kB. Int J Radiat Oncol Biol Phys 50 (2001) 183-193
10. Denlinger C.E., Rundall B.K., Keller M.D., and Jones D.R. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 4 October (78) (2004) 1207-1214
11. Jung C.S., Zhou Z., and Khuri F.R. Sun SY assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biol Ther 6 May (5) (2007) 749-754
12. Mortenson M.M., Schlieman M.G., Virudachalam S., and Bold R.J. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother Pharmacol 54 October (4) (2004) 343-353
13. Fanucchi M.P., Fossella F.V., and Belt R. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24 November (31) (2006) 5025-5033
14. Davies A.M., Ruel C., Lara P.N., Lau D.H., Gumerlock P.H., Bold R., et al. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. J Thorac Oncol 3 January (1) (2008) 68-74
15. Ma C., Mandrekar S.J., and Alberts S.R. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 59 February (2) (2007) 207-215
16. Edelman M.J. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer 7 October (Suppl. 2) (2005) S64-S66
17. ATS Board of Directors, and ERS Executive Committee. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 156 (1997) 320-332
18. Furuse K., Fukuoka M., Kawahaa M., Nishikawa H., Takada, Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17 September (9) (1999) 2692-2699
19. Curran W.J., Scott C., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer Initial report of RTOG 9410. Proc Am Soc Clin Oncol 19 (2000) 484a
20. Martin J., Ginsberg R.J., Abolhoda A., Bains M.S., Downey R.J., Korst R.J., et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 4 October (72) (2001) 1149-1154
21. Daly B.D., Fernando H.C., Ketchedjian A., Dipetrillo T.A., Kachnic L.A., Morelli D.M., et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung cancer. Ann Thorac Surg 82 July (1) (2006) 227-231
22. Van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., and Schramel F. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
23. Sonett J.R., Suntharalingam M., Edelman M.J., Patel A.B., Gamliel Z., Doyle A., et al. Induction curative intent radiotherapy (>59GY) and concurrent chemotherapy with surgical resection in locally advanced non-small cell lung cancer: operative feasibility and mid-term survival. Ann Thorac Surg 78 October (4) (2004) 1200-1205 [discussion 1206]
24. Gamliel Z., Burrows W., Sonnett J.R., Suntharalingam M., Edelman M.J., Hausner P.F., et al. Pneumonectomy for lung cancer can be performed safely following preoperative concurrent chemotherapy and high-dose radiation. Presented at the forty-second annual meeting of the society of thoracic surgeons. Chicago, Illinois, January 31, 2006 (2006) Control number: 326
25. Gotoh A., Ohyashiki K., Oshimi K., Usui N., Hotta T., Dan K., et al. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol 84 December (5) (2006) 406-412